Skip to main content

Table 1 Baseline characteristics of patients with acute myocardial infarction in non-COVID-19 and COVID-19 pandemic periods

From: Reconsidering treatment guidelines for acute myocardial infarction during the COVID-19 pandemic

 

AMI

STEMI

NSTEMI

Group 1

(n = 254)

Group 2

(n = 124)

p-value

Group 1

(n = 153)

Group 2

(n = 81)

p-value

Group 1

(n = 101)

Group 2(n = 43)

p-value

Age, years, mean ± SD/median(IQR)

64 (57.0,72.0)

64 (55.3,70.0)

0.306

63.1 ± 12.6

62.7 ± 11.6

0.809

68.0 (59.0,72.0)

66.0 (56.0,71.0)

0.211

Gender/male, n (%)

190 (74.8)

95 (76.6)

0.701

114 (74.5)

62 (76.5)

0.732

76 (75.3)

33 (76.7)

0.848

Diabetes mellitus, n (%)

86 (35.5)

36 (34.3)

0.823

48 (32.0)

26 (34.7)

0.688

38 (41.3)

10 (33.3)

0.438

Hypertension, n (%)

157 (64.9)

62 (59.0)

0.301

98 (65.3)

45 (60.0)

0.433

59 (64.1)

17 (56.7)

0.464

Prior MI, n (%)

14 (5.8)

11 (10.5)

0.121

3 (2.0)

4 (5.3)

0.342

11 (12.0)

7 (23.3)

0.219

Prior CAD, n (%)

11 (4.5)

5 (4.8)

0.930

3 (2.0)

2 (2.7)

1.000

8 (8.7)

3 (10.0)

1.000

Prior PCI, n (%)

18 (92.6)

11 (10.5)

0.348

9 (6.0)

6 (8.0)

0.571

9 (9.8)

5 (16.7)

0.486

Prior CABG, n (%)

7 (2.9)

3 (2.9)

0.986

4 (2.7)

1 (1.3)

0.873

3 (3.3)

2 (6.7)

0.774

Smoker, n (%)

154 (71.6)

61 (28.4)

0.329

96 (64.0)

40 (53.3)

0.123

58 (63.0)

21 (70.0)

0.489

Alcohol use, n (%)

75 (31.0)

37 (35.2)

0.437

47 (31.3)

26 ( 34.7)

0.615

28 (30.4)

11 (36.7)

0.525

Systolic pressure (mmHg), mean ± SD/median (IQR)

139 (126.0,159.5)

145 (123.0,160.0)

0.476

141.1 ± 23.2

145.3 ± 30.3

0.288

139.0 (125.5,160.0)

142.0 (125.0,154.0)

0.441

Diastolic pressure (mm Hg), mean ± SD/median (IQR)

82 (72.0,95.0)

87 (73.8,98.0)

0.101

85.0 ± 16.9

88.3 ± 18.2

0.168

82.0 ± 14.4

84.3 ± 17.2

0.416

Heart rate (beats per min), median (IQR)

76 (66.0,90.0)

80.5 (71.0,93.0)

0.017*

75.0 (64.0,89.0)

80.0 (69.0,88.0)

0.047

78.0 (70.0,91.0)

82.0 (76.0,100.0)

0.015

cTNI (ng/mL),median (IQR)

1.20 (0.63,2.46)

1.23 (0.65,3.08)

0.618

1.14 (0.60,2.16)

1.23 (0.69,3.62)

0.188

1.22 (0.65,2.76)

1.10 (0.36,2.13)

0.377

LVEF, median (IQR)

50 (42.3,56.0)

50 (41.0,56.0)

0.647

48.0 (42.0,55.0)

50.0 (42.0,55.0)

0.368

55.0 (45.0,57.0)

52.0 (42.0,56.0)

0.193

Arrhythmia, n (%)

19 (7.4)

11 (8.9)

0.639

11 (7.2)

8 (9.9)

0.474

8 (7.9)

3 (7.0)

0.845

 Atrial fibrillation

8 (3.1)

4 (3.2)

 

5 (3.3)

3 (3.7)

 

3 (3.0)

1 (2.3)

 

 Ventricular tachycardia

4 (1.6)

3 (2.4)

 

2 (1.3)

2 (2.5)

 

2 (2.0)

1 (2.3)

 

 Ventricular fibrillation

3 (1.2)

2 (1.6)

 

2 (1.3)

2 (2.5)

 

1 (1.0)

0 (0)

 

 Atrioventricular block III

4 (1.6)

2 (1.6)

 

2 (1.3)

1 (1.2)

 

2 (2.0)

1 (2.3)

 

Killip class, n (%)

        

0.084

 1

218 (95.6)

109 (94.0)

0.482

136 (97.1)

74 (98.7)

0.611

82 (93.2)

35 (85.4)

 

 2

8 (3.5)

3 (2.6)

  

2 (1.4)

0 (0.0)

 

6 (6.8)

3 (7.3)

 3

1 (0.4)

3 (2.6)

  

1 (0.7)

1 (1.3)

 

0 (0.0)

2 (4.9)

 4

1 (0.4)

1 (0.9)

  

1 (0.7)

0 (0.0)

 

0 (0.0)

1 (2.4)

Very-high risk#, n (%)

      

19 (18.8)

13 (30.2)

0.131

  1. COVID-19 coronavirus disease 2019, AED accident and emergency department, CABG coronary artery bypass graft, ECG electrocardiogram, MI myocardial infarction, NSTEMI non-ST elevation myocardial infarction, PCI percutaneous coronary intervention, STEMI ST elevation myocardial infarction, LVEF left ventricular ejection fraction, cTNT cardiac troponin T, IQR interquartile range
  2. #Risk stratification according to 2015 ESC guidelines of NSEMI *P < 0.05